Analysis Tools
growth/size/body
|
• mice treated with ganciclovir exhibit an increase in spleen weight
• however, platelet number, hemoglobin level and mean corpuscular volume are normal in ganciclovir treated mice
|
hematopoietic system
|
• mice treated with ganciclovir exhibit an increase in spleen weight
• however, platelet number, hemoglobin level and mean corpuscular volume are normal in ganciclovir treated mice
|
|
• mice treated with ganciclovir to ablate osteoblasts show a loss of bone marrow cellularity
|
|
• mice treated with ganciclovir show a decrease in the number of osteoclasts in all regions of the tibia
(J:112520)
• however, osteocytes are still present in the cortical and trabecular bone
(J:112520)
• recovery from ganciclovir treatment for 28 days results in a large increase in bone mass and returns osteoclast parameters to normal levels
(J:112520)
|
|
 |
• mice treated with ganciclovir and pamidronate show a reduced number of osteoclasts
(J:217781)
|
immune system
|
• mice treated with ganciclovir exhibit an increase in spleen weight
• however, platelet number, hemoglobin level and mean corpuscular volume are normal in ganciclovir treated mice
|
|
• mice treated with ganciclovir show a decrease in the number of osteoclasts in all regions of the tibia
(J:112520)
• however, osteocytes are still present in the cortical and trabecular bone
(J:112520)
• recovery from ganciclovir treatment for 28 days results in a large increase in bone mass and returns osteoclast parameters to normal levels
(J:112520)
|
|
|
|
• mice treated with ganciclovir and pamidronate show a reduced number of osteoclasts
(J:217781)
|
skeleton
|
• mice treated with ganciclovir show a decrease in the number of osteoclasts in all regions of the tibia
(J:112520)
• however, osteocytes are still present in the cortical and trabecular bone
(J:112520)
• recovery from ganciclovir treatment for 28 days results in a large increase in bone mass and returns osteoclast parameters to normal levels
(J:112520)
|
|
|
|
• mice treated with ganciclovir and pamidronate show a reduced number of osteoclasts
(J:217781)
|
|
|
• mice treated with ganciclovir and pamidronate show a shift in the mineral distribution toward a more hypermineralized profile
|
|
|
• mice treated with ganciclovir and pamidronate show an increase in areal bone mineral density in femurs
|
|
|
• mice treated with ganciclovir and pamidronate show an increase in areal bone mineral density in femurs
|
|
|
• mice treated with ganciclovir and pamidronate exhibit a higher trabecular bone volume, trabecular thickness, and trabecular number
|
|
• mice treated with ganciclovir show loss of all osteoblasts that normally line trabecular and endosteal surfaces
|
|
|
• mice treated with ganciclovir and pamidronate exhibit a higher trabecular number
|
|
|
• mice treated with ganciclovir and pamidronate exhibit a higher trabecular thickness
|
|
|
• mice treated with ganciclovir to ablate osteoblasts and pamidronate to inhibit osteoclastic resorption at 4 months of age exhibit a reduction in bone formation
|
|
|
• mice treated with ganciclovir and pamidronate show increased homogeneity in the degree of bone mineralization of the L3 vertebrae, with a 20% narrowing of the full width at half maximum height of the bone mineral density distribution
|
|
|
• mice treated with ganciclovir and pamidronate show inhibition of bone resorption
|
|
|
• L6 vertebral bodies from mice treated with ganciclovir and pamidronate exhibit increased stiffness
|
|
|
• in vertebral compression tests, mice treated with ganciclovir and pamidronate exhibit L6 vertebral bodies with decreased failure displacement, energy to failure, normalized failure strain, and toughness and increased stiffness and normalized Youngs modulus
• in three-point bending tests, femoral mid-diaphyses from ganciclovir and pamidronate treated mice show increased failure displacement, energy to failure, normalized failure to strain, and toughness, but do not show differences in stiffness or Youngs modulus
|
